세계의 출혈성 질환 치료 시장 보고서(2025년)
Bleeding Disorders Treatment Global Market Report 2025
상품코드 : 1821537
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

출혈성 질환 치료 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 8.9%로 259억 3,000만 달러로 성장합니다. 예측 기간의 성장은 고령화, 맞춤형 의료, 환자 옹호 및 지원, 가처분 소득 증가, 의료비 지출 증가에 기인합니다. 예측 기간의 주요 동향으로는 개인 맞춤형 치료 계획, 원격의료 서비스 확대, 첨단 응고인자 치료, RNA 기반 치료, 희귀질환 치료제 지정 접근성 등이 있습니다.

향후 5년간 8.9%의 성장률 전망은 지난번 전망치보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰은 아일랜드와 벨기에에서 개발된 유전자 재조합 응고인자 및 유전자 치료용 벡터의 가격을 급등시켜 치료 격차 및 전문 약국 지출 증가를 가져와 미국의 혈우병 치료에 지장을 초래할 수 있습니다. 또한 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

출혈성 질환 치료제 시장의 성장은 혈우병으로 진단받은 환자 수가 증가함에 의해 촉진될 것으로 예측됩니다. 혈우병은 혈액 응고 장애를 특징으로 하는 유전성 출혈성 질환으로, 치료에는 보충 요법이 필요합니다. 이는 결핍된 혈액응고인자를 인간 혈장 농축제제 또는 재조합 혈액응고인자 VIII 또는 IX로 대체하는 것을 포함합니다. 2021년 세계혈우연맹은 전 세계에서 약 23만 4,000명의 혈우병 환자가 확인되었다고 보고했습니다. 혈우병 진단 환자 수 증가는 출혈성 질환 치료제 시장의 성장을 지원하는 중요한 요인으로, 이 유전성 질환에 대한 치료법 발전의 중요성을 강조하고 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Bleeding disorders constitute a category of medical conditions characterized by inadequate blood clotting, leading to prolonged bleeding following surgery, injury, menstruation, or trauma. The management of these disorders aims to either arrest or diminish the frequency of bleeding episodes.

Key modalities in the treatment of bleeding disorders encompass desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic or clot-stabilizing medications, fibrin sealants, drugs for topical application on cuts, and pipeline analysis. Desmopressin (DDAVP) therapies play a pivotal role in diagnosing individuals with mild hemophilia A or von Willebrand disease, effectively halting bleeding. Targeted diseases include hemophilia A, hemophilia B, von Willebrand disease, liver disease, and others. These interventions cater to diverse end users, including hospitals, clinics, specialty clinics, research institutes, and related entities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The bleeding disorders treatment market research report is one of a series of new reports from The Business Research Company that provides Bleeding disorders treatment market statistics, including bleeding disorders treatment industry global market size, regional shares, competitors with bleeding disorders treatment market share, detailed Bleeding disorders treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the bleeding disorders treatment industry. This bleeding disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bleeding disorders treatment market size has grown strongly in recent years. It will grow from $16.95 billion in 2024 to $18.45 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased patient awareness, access to healthcare, advancements in hemophilia therapies, global market expansion.

The bleeding disorders treatment market size is expected to see strong growth in the next few years. It will grow to $25.93 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to aging population, personalized medicine, patient advocacy and support, rise in disposable income, rise in healthcare expenditure. Major trends in the forecast period include personalized treatment plans, expansion of telehealth services, advanced clotting factor therapies, rna-based treatments, access to orphan drug designation.

The forecast of 8.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. hemophilia care by inflating prices of recombinant clotting factors and gene therapy vectors developed in Ireland and Belgium, resulting in treatment gaps and higher specialty pharmacy expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the bleeding disorders treatment market is anticipated to be propelled by the increasing number of diagnosed hemophilia patients. Hemophilia, an inherited bleeding disorder characterized by inadequate blood clotting, necessitates replacement therapy for treatment. This involves replacing the deficient blood clotting factors with human plasma concentrates or recombinant forms of clotting factors VIII or IX. In 2021, the World Federation of Hemophilia reported nearly 234,000 confirmed cases of hemophilia worldwide. The escalating number of diagnosed hemophilia patients is a significant driver behind the growth of the bleeding disorders treatment market, emphasizing the importance of advancing treatments for this inherited disorder.

The increasing healthcare expenditure is expected to fuel the growth of the bleeding disorders treatment market in the coming years. Healthcare expenditure refers to the total spending on healthcare costs, encompassing all money allocated to healthcare-related goods and services within a specific healthcare system or economy. This expenditure is vital for supporting the development and accessibility of treatments for bleeding disorders. For example, in October 2024, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported that the health spending share of GDP rose from 17.3 percent in 2022 to 19.7 percent in 2032. Thus, the rise in healthcare expenditure is driving the expansion of the bleeding disorders treatment market.

Major companies in the bleeding disorder treatment market are concentrating on the development of innovative technologies, such as single-dose treatments, to improve treatment efficacy and enhance patient quality of life by reducing the necessity for ongoing therapies. Single-dose treatment refers to a therapeutic strategy that provides a complete treatment with a single administration, aiming for long-lasting effects without the requirement for multiple doses. For example, in June 2023, BioMarin Pharmaceutical Inc., a US-based biotechnology firm, introduced BioMarin's ROCTAVIANTM (valoctocogene roxaparvovec-rvox). ROCTAVIAN is specifically designed for adults with severe hemophilia A (characterized by FVIII activity levels below 1 IU/dL) who do not have pre-existing antibodies to adeno-associated virus serotype 5 (AAV5) as confirmed by an FDA-approved test.

Leading companies in the bleeding disorder treatment market are actively developing on-demand treatments to control bleeding episodes and perioperative management solutions, addressing a broader customer base and aiming to boost sales and revenue. On-demand treatment is a crucial aspect of managing bleeding disorders, empowering individuals to respond promptly to bleeding episodes and ensuring safe perioperative care during surgical procedures. Ongoing advances in clotting factor therapies and treatment strategies are enhancing the overall quality of life for individuals with bleeding disorders, enabling them to lead more active and fulfilling lives. In February 2023, the collaboration between Sanofi and Sobi resulted in the development of the first-in-class, high-sustained factor VIII replacement therapy known as ALTUVIIIO, which received U.S. FDA approval. This groundbreaking medication offers a unique once-a-week dosing schedule, producing factor activity levels above 40% for the majority of the week and significantly reducing bleeding compared to previous factor VIII prophylaxis.

In October 2022, Pfizer Inc., a prominent U.S.-based pharmaceutical and biotechnology corporation, made a strategic move by acquiring Global Blood Therapeutics, Inc. (GBT) for an undisclosed amount. This acquisition was geared towards leveraging GBT's portfolio to expedite discovery processes and provide a range of potential best-in-class medicines for patients with sickle cell disease. Global Blood Therapeutics, Inc., a U.S.-based biopharmaceutical company specializing in the treatment of blood disorders, contributed valuable expertise and products to Pfizer's portfolio, aligning with the broader industry trend of strategic acquisitions to strengthen capabilities and enhance the range of therapeutic offerings in the bleeding disorder treatment market.

Major companies operating in the bleeding disorders treatment market include AbbVie Inc., Bayer AG, Novo Nordisk A/S, Pfizer Inc., Biogen Inc., CSL Behring Company, Grifols SA, Octapharma AG, BDI Pharma Inc., Ferring Pharmaceuticals Ltd., Xenetic Biosciences Inc., Sanofi SA, Alnylam Pharmaceuticals Inc., Novartis AG, Shire plc, Novo Nordisk, Grifols SA, F. Hoffmann-La Roche AG, Sanofi Corporation, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Biotest AG, LFB S.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., HEMA Biologics LLC, ADMA Biologics Inc., Grifols Biologicals Inc., Octapharma Plasma Inc., Kedrion Biopharma Inc., BPL Plasma Inc., BioLife Plasma Services, CSL Plasma Ltd., Grifols Shared Services North America Inc., Octapharma USA Inc., Shire US Inc., Pfizer Canada Inc., Grifols Canada Ltd., Octapharma Canada Inc.

North America was the largest region in the bleeding disorders treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the bleeding disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The bleeding disorders treatment market includes revenues earned by entities by recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bleeding Disorders Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bleeding disorders treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for bleeding disorders treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bleeding disorders treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Bleeding Disorders Treatment Market Characteristics

3. Bleeding Disorders Treatment Market Trends And Strategies

4. Bleeding Disorders Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Bleeding Disorders Treatment Growth Analysis And Strategic Analysis Framework

6. Bleeding Disorders Treatment Market Segmentation

7. Bleeding Disorders Treatment Market Regional And Country Analysis

8. Asia-Pacific Bleeding Disorders Treatment Market

9. China Bleeding Disorders Treatment Market

10. India Bleeding Disorders Treatment Market

11. Japan Bleeding Disorders Treatment Market

12. Australia Bleeding Disorders Treatment Market

13. Indonesia Bleeding Disorders Treatment Market

14. South Korea Bleeding Disorders Treatment Market

15. Western Europe Bleeding Disorders Treatment Market

16. UK Bleeding Disorders Treatment Market

17. Germany Bleeding Disorders Treatment Market

18. France Bleeding Disorders Treatment Market

19. Italy Bleeding Disorders Treatment Market

20. Spain Bleeding Disorders Treatment Market

21. Eastern Europe Bleeding Disorders Treatment Market

22. Russia Bleeding Disorders Treatment Market

23. North America Bleeding Disorders Treatment Market

24. USA Bleeding Disorders Treatment Market

25. Canada Bleeding Disorders Treatment Market

26. South America Bleeding Disorders Treatment Market

27. Brazil Bleeding Disorders Treatment Market

28. Middle East Bleeding Disorders Treatment Market

29. Africa Bleeding Disorders Treatment Market

30. Bleeding Disorders Treatment Market Competitive Landscape And Company Profiles

31. Bleeding Disorders Treatment Market Other Major And Innovative Companies

32. Global Bleeding Disorders Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bleeding Disorders Treatment Market

34. Recent Developments In The Bleeding Disorders Treatment Market

35. Bleeding Disorders Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기